Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Neoplasm Metastasis 1Cholangiocarcinoma 1

Interventions

Oxaliplatin 297Fluorouracil 272Bevacizumab 235Gemcitabine 234Leucovorin 212Capecitabine 204pembrolizumab 200Nivolumab 157Irinotecan 156Cisplatin 148Specimen Handling 143Magnetic Resonance Spectroscopy 130130-nm albumin-bound paclitaxel 115Paclitaxel 109durvalumab 104Cetuximab 102Radiotherapy 96atezolizumab 92Biopsy 92Drug Therapy 91Albumin-Bound Paclitaxel 78tislelizumab 77Taxes 73Folfox protocol 68lenvatinib 67Carboplatin 65regorafenib 60Blood Specimen Collection 60trifluridine tipiracil drug combination 52Ipilimumab 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
infigratinib × Gastrointestinal × 1 year × Clear all
NCT04233567 2026-02-24

Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
17 enrolled 12 charts
Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡